STN: BLA 125700
Proper Name: nadofaragene firadenovec-vncg
Tradename: ADSTILADRIN
Manufacturer: Ferring Pharmaceuticals A/S
Indication: 

  • ADSTILADRIN is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Product Information

Supporting Documents

 

  • Content current as of:

    10/10/2025

Source